Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
Aethlon Medical (Nasdaq: AEMD) will release fiscal second quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 at 4:15 p.m. ET. Management will host a conference call the same day at 4:30 p.m. ET to review results and recent corporate developments, followed by a Q&A.
Registered participants will receive dial-in instructions; toll-free and international dial-in numbers are provided. A replay will be available approximately one hour after the call through December 12, 2025 via the company website or provided dial-in numbers (replay ID 1454680).
The release reiterates that Aethlon is advancing the investigational Hemopurifier, an extracorporeal device targeting enveloped viruses and tumor-derived extracellular vesicles, and notes its U.S. FDA Breakthrough Device Designation for specified oncology and viral indications.
Aethlon Medical (Nasdaq: AEMD) annuncerà i risultati fiscali del secondo trimestre per il periodo terminato il 30 settembre 2025 mercoledì 12 novembre 2025 alle ore 16:15 ET. La direzione terrà una conference call lo stesso giorno alle 16:30 ET per rivedere i risultati e gli sviluppi aziendali recenti, seguita da una sessione di domande e risposte.
I partecipanti registrati riceveranno le istruzioni per chiamare; sono forniti numeri gratuiti e internazionali. Una replica sarà disponibile circa un'ora dopo la chiamata fino al 12 dicembre 2025 tramite il sito dell'azienda o i numeri forniti (ID replay 1454680).
Il comunicato ribadisce che Aethlon sta avanzando con l'investigational Hemopurifier, un dispositivo extracorporeo che mira a virus avvolti e a vesicole extracellular derivanti da tumori, e segnala la sua Breakthrough Device Designation della FDA statunitense per specifiche indicazioni oncologiche e virali.
Aethlon Medical (Nasdaq: AEMD) publicará los resultados del segundo trimestre fiscal para el periodo terminado el 30 de septiembre de 2025 el miércoles 12 de noviembre de 2025 a las 4:15 p.m. ET. La dirección realizará una llamada de conferencia ese mismo día a las 4:30 p.m. ET para revisar los resultados y los desarrollos corporativos recientes, seguida de una sesión de preguntas y respuestas.
Los participantes registrados recibirán instrucciones para marcar; se proporcionarán números de marcación gratuitos e internacionales. Habrá una reproducción disponible aproximadamente una hora después de la llamada hasta el 12 de diciembre de 2025 a través del sitio web de la empresa o de los números de marcación proporcionados (ID de reproducción 1454680).
El comunicado reiterará que Aethlon está avanzando con el Hemopurifier, un dispositivo extracorpóreo que apunta a virus envueltos y a vesículas extracelulares derivadas de tumores, y señala su Designación de Dispositivo Breakthrough de la FDA de EE. UU. para indicaciones oncológicas y virales especificadas.
Aethlon Medical (Nasdaq: AEMD)는 2025년 9월 30일로 끝나는 기간에 대한 회계 연간 제2분기 실적을 2025년 11월 12일 수요일 오후 4시 15분(동부표준시)에 발표합니다. 경영진은 같은 날 오후 4시 30분(ET)에 실적 및 최근 기업 개발 사항을 검토하는 컨퍼런스 콜을 개최하며 질의응답도 이어집니다.
등록 참가자들은 다이얼 인 지침을 받게 되며, 무료 및 국제 다이얼 인 번호가 제공됩니다. 콜 이후 약 한 시간 후인 2025년 12월 12일까지 회사 웹사이트나 제공된 다이얼 인 번호를 통해 재생이 가능합니다(재생 ID 1454680).
발표는 또 Hemopurifier의 개발 진행을 강조하며, 이는 외부순환 장치로 포장된 바이러스와 종양에서 유래한 세포외 소포를 겨냥하고, 특정 종양 및 바이러스 적응에 대한 미국 FDA의 Breakthrough Device Designation를 받았다고 명시합니다.
Aethlon Medical (Nasdaq : AEMD) publiera les résultats du deuxième trimestre fiscal pour la période se terminant le 30 septembre 2025 le mercredi 12 novembre 2025 à 16 h 15 ET. La direction organisera le même jour une conférence téléphonique à 16 h 30 ET afin de passer en revue les résultats et les développements récents de l'entreprise, suivie d'une session de questions-réponses.
Les participants enregistrés recevront les instructions pour composer; des numéros d'appel gratuits et internationaux seront fournis. Une rediffusion sera disponible environ une heure après l'appel jusqu'au 12 décembre 2025 via le site Web de l'entreprise ou les numéros fournis (ID de rediffusion 1454680).
Le communiqué réitère qu'Aethlon fait progresser l'Hemopurifier, un dispositif extrcorpore ciblant les virus enveloppés et les vésicules extracellulaires dérivées de tumeurs, et note sa désignation FDA Breakthrough Device pour des indications oncologiques et virales spécifiées.
Aethlon Medical (Nasdaq: AEMD) wird die Finanzergebnisse des zweiten Quartals für den Zeitraum bis zum 30. September 2025 am Mittwoch, dem 12. November 2025 um 16:15 Uhr ET veröffentlichen. Die Geschäftsführung wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um Ergebnisse und aktuelle Unternehmensentwicklungen zu besprechen, gefolgt von einer Fragerunde.
Registrierte Teilnehmer erhalten Dial-in-Anweisungen; kostenlose und internationale Telefonnummern werden bereitgestellt. Etwa eine Stunde nach dem Anruf wird eine Wiederholung bis zum 12. Dezember 2025 über die Website des Unternehmens oder die angegebenen Dial-in-Nummern (Wiederholungs-ID 1454680) verfügbar sein.
Die Mitteilung bekräftigt, dass Aethlon mit dem fortschnittlichen Hemopurifier voranschreitet, einem extracorporealen Gerät, das auf umhüllte Viren und tumorderivierte extrazelluläre Vesikel abzielt, und verweist auf die FDA Breakthrough Device Designation für bestimmte onkologische und virale Indikationen.
Aethlon Medical (نطاق Nasdaq: AEMD) ستصدر نتائج الربع المالي الثاني للفترة المنتهية في 30 سبتمبر 2025 يوم الأربعاء 12 نوفمبر 2025 الساعة 4:15 مساءً بتوقيت شرق الولايات المتحدة. ستعقد الإدارة مكالمة مؤتمرية في نفس اليوم عند 4:30 مساءً بتوقيت شرق الولايات المتحدة لمراجعة النتائج والتطورات المؤسسية الأخيرة، تليها جلسة أسئلة وأجوبة.
سيتلقى المشاركون المسجلون تعليمات الاتصال؛ وسيتم توفير أرقام اتصال مجانية ودولية. ستكون هناك إعادة تشغيل متاحة نحو ساعة بعد الاتصال وحتى 12 ديسمبر 2025 عبر موقع الشركة على الويب أو الأرقام المقدمة (معرّف إعادة التشغيل 1454680).
يؤكد البيان أن Aethlon يقدّم Hemopurifier التجريبي، وهو جهاز خارج الجسم يستهدف الفيروسات المغلفة والحويّات خارج الخلية المستمدة من الأورام، ويشير إلى تصنيف FDA Breakthrough Device لبعض الاستخدامات السرطانية والفيروسية المحددة.
- None.
- None.
Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/1005d2109f4. Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through December 12, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international) or
About the Hemopurifier®
The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.
The Hemopurifier holds a
The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in
For more information, visit www.AethlonMedical.com and follow the company on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-second-quarter-financial-results-and-host-conference-call-on-november-12-2025-302608181.html
SOURCE Aethlon Medical, Inc.
FAQ
When will Aethlon Medical (AEMD) release Q2 2025 financial results?
What time is the Aethlon Medical (AEMD) conference call for the November 12, 2025 results?
How can investors register or join the Aethlon Medical (AEMD) conference call on November 12, 2025?
Will a replay of the Aethlon Medical (AEMD) November 12, 2025 call be available and for how long?
What is the Hemopurifier and what designations does it hold according to Aethlon Medical (AEMD)?
